Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Head and Neck Neoplasms 3Prostatic Neoplasms 2Mouth Neoplasms 2Brain Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Oligodendroglioma 1Neuroblastoma 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lung Neoplasms 1Kidney Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1Astrocytoma 1

Interventions

Carboplatin 195Cisplatin 117Paclitaxel 107Pemetrexed 106Docetaxel 96Gemcitabine 89Radiotherapy 83Erlotinib Hydrochloride 58Bevacizumab 55Etoposide 49durvalumab 39pembrolizumab 38Nivolumab 31Specimen Handling 30Magnetic Resonance Spectroscopy 30Irinotecan 27Radiosurgery 26osimertinib 24Gefitinib 24Drug Therapy 23Vinorelbine 22atezolizumab 20Topotecan 20Radiation 16Cetuximab 16Taxes 15Surgical Procedures, Operative 14Neoadjuvant Therapy 13Filgrastim 13Chemotherapy, Adjuvant 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lung Neoplasms × Fenretinide × Clear all
NCT00009971 2013-02-11

Fenretinide in Treating Patients With Recurrent Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Completed
32 enrolled
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡